Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2109172 | 0.84 | VDR (0.41) | CYSLTR2CYSLTR1BCHEFFAR1SPHK1 | |
| SCHEMBL6155571 | 0.83 | VDR (0.46) | CYSLTR2CYSLTR1BCHEFFAR1ALOX5 | |
| SCHEMBL6155587 | 0.82 | CYSLTR2 (0.44) | CYSLTR2CYSLTR1BCHEFFAR1ALOX5 | |
| SCHEMBL6155242 | 0.81 | VDR (0.44) | CYSLTR2CYSLTR1BCHEFFAR1SPHK1 | |
| SCHEMBL6155601 | 0.79 | CYSLTR2 (0.39) | CYSLTR2CYSLTR1BCHEFFAR1ALOX5 | |
| SCHEMBL6155248 | 0.79 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1BCHEFFAR1ALOX5 | |
| SCHEMBL2107787 | 0.79 | VDR (0.40) | CYSLTR2CYSLTR1BCHEFFAR1 | |
| SCHEMBL6155474 | 0.75 | CYSLTR2 (0.45) | CYSLTR2CYSLTR1FFAR1ALOX5KMT2A | |
| SCHEMBL2107789 | 0.75 | MRGPRX4 (0.44) | CYSLTR2CYSLTR1BCHEFFAR1ALOX5 | |
| SCHEMBL6156188 | 0.75 | ADRB1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1282636-C | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2006-11-01 | — | — | CN | claimed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | claimed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | claimed |
| CN-1332711-A | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2002-01-23 | — | — | CN | claimed |
| EP-2879656-B2 | DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE | OREAL (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-11730682-B2 | Self-standing cosmetic sheet | L'OREAL (FR) | 2023-08-22 | — | — | US | disclosed |
| EP-2836187-B1 | SELF-STANDING COSMETIC SHEET | OREAL (FR) | 2021-12-08 | — | — | EP | disclosed |
| EP-2879656-B1 | DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE | OREAL (FR) | 2019-05-29 | — | — | EP | disclosed |
| US-10226411-B2 | Dyeing composition comprising a fatty substance, a non-ionic guar gum, an amphoteric surfactant and a non-ionic or anionic surfactant, and an oxidizing agent, dyeing process and suitable device | L'OREAL (FR) | 2019-03-12 | — | — | US | disclosed |
| US-10201483-B2 | Dye composition in cream form comprising at least one oil and little or no solid fatty alcohol, dyeing process and suitable device | L'OREAL (FR) | 2019-02-12 | — | — | US | disclosed |
| EP-2879649-B1 | DYEING COMPOSITION COMPRISING AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE OXIDIZING AGENT AND AT LEAST ONE NON-IONIC, ANIONIC AND AMPHOTERIC SURFACTANT | OREAL (FR) | 2018-11-07 | — | — | EP | disclosed |
| US-20180235849-A1 | SELF-STANDING COSMETIC SHEET | L'OREAL (FR) | 2018-08-23 | — | — | US | disclosed |
| EP-1559398-A1 | Process for preparing a composition for the cosmetic treatment of keratinous materials on the basis of a pressurised fluid and vitamins | L'OREAL (FR) | 2005-08-03 | — | — | EP | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | L'OREAL (FR) | 2002-12-26 | — | — | US | disclosed |
| EP-1262168-A1 | Composition containing fibres to combat the skin aging process | L'OREAL (FR) | 2002-12-04 | — | — | EP | disclosed |
| CN-1332711-A | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2002-01-23 | — | — | CN | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10226411-B2 | Dyeing composition comprising a fatty substance, a non-ionic guar gum, an amphoteric surfactant and a non-ionic or anionic surfactant, and an oxidizing agent, dyeing process and suitable device | KRT18, OAT, DSG1 | CYSLTR2 2051/4885CYSLTR1 1868/4885BCHE 2477/4885 |
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | CYP24A1, CYP27B1, CYP2R1 | CYSLTR2 4433/4885CYSLTR1 4236/4885BCHE 569/4885 |
| US-10201483-B2 | Dye composition in cream form comprising at least one oil and little or no solid fatty alcohol, dyeing process and suitable device | KRT18, CUTA, DSG1 | CYSLTR2 1935/4885CYSLTR1 1818/4885BCHE 3171/4885 |
| US-20180235849-A1 | SELF-STANDING COSMETIC SHEET | CUTA, DSG1, SUCLG1 | CYSLTR2 2427/4885CYSLTR1 2592/4885BCHE 1497/4885 |
| US-11730682-B2 | Self-standing cosmetic sheet | CUTA, DSG1, SUCLG1 | CYSLTR2 2427/4885CYSLTR1 2592/4885BCHE 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.